×

Biotech and Pharmaceuticals Pharmaceuticals

  • Web page for Pfizer's Elelyso

    Pfizer paid a "nominal fee" to cover expenses related to the facility inspection, and to obtain a certification, a Pfizer spokeswoman said.

  • Actavis completes deal to buy Forest Labs

    The idea is to keep the generic DNA but not the generic margins, says Brent Saunders, Actavis CEO, discussing his company's acquisition of Forest Labs and its long-term growth plans. Saunders also weighs in on corporate tax reform.

  • Wild ride for MannKind's Afrezza

    The FDA approved MannKind's inhaled insulin drug Afrezza. CNBC's Meg Tirrell has the details of the approval.

  • Pfizer to make new AstraZeneca bid?

    Kokou Agbo-Bloua, head of equity and derivative strategy for Europe at BNP Paribas, says that Pfizer is likely to submit another bid to acquire AstraZeneca as a deal would still make "a lot of sense".

  • Vertex CEO on big cystic fibrosis breakthrough

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."

  • Cystic fibrosis breakthrough

    CNBC's Meg Tirrell explains how cystic fibrosis occurs in the body, and the breakthrough announcement from Vertex Pharmaceuticals.

  • Road ahead for Vertex

    Discussing the possibility of success for Vertex Pharmaceuticals' cystic fibrosis drugs, and what it means for the stock, with Matt Roden, UBS executive director.

  • Vertex soars on cystic fibrosis innovation

    CNBC's Meg Tirrell reports Vertex Pharmaceuticals' cystic fibrosis combination of Kalydeco and Lumacaftor has expanded their patient population.

  • Vertex's cystic fibrosis breakthrough

    CNBC's Meg Tirell reports Vertex Pharmaceuticals' treatment for cystic fibrosis has succeeded in late stage trials. Vertex will now file applications for U.S. and Europe approval in Q4.

  • Vertex's biotech breakthrough

    CNBC's Meg Tirrell reports the pharmaceutical company has developed a new drug that significantly improves lung function in the treatment of cystic fibrosis.

  • Cubist advances Sivextro

    Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.

  • A doctor draws Allergan's Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California.

    Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.

  • Drug prices under pressure

    CNBC's Meg Tirrell reports on the mounting competition among pharmaceutical companies for the treatment of hepatitis C and macular degeneration.

  • Can Shire defend itself against AbbVie takeover?

    Shire's defense against an AbbVie's takeover lies in its "credible" management team and "pretty successful strategy". However, AbbVie's offer seems to include a "huge premium", CNBC's Catherine Boyle reports.

  • Forces driving market higher

    CNBC's Dominic Chu discusses the break out of Kite Pharma, and independent investment consultant David Darst, explains why the stock market has not responded to higher oil prices, and names four goals that will move the market higher.

  • Cramer: AbbVie-Shire driven by inversion

    British drug maker Shire has rejected a $46 billion takeover offer from U.S. based AbbVie. CNBC's Jim Cramer discusses the latest attempt by a U.S. health care company to tap into the low foreign tax rate.

  • Botox by Allergan

    Valeant said it plans to launch an exchange offer to Allergan shareholders this week, soliciting proxies to call for a meeting to discuss its offer.

  • Stéphane Bancel, president and founding CEO, Moderna Therapeutics

    AstraZeneca has invested $240 million in Moderna Therapeutics to license its technology, which uses messenger RNA therapy to fight cancer.

  • Medtronic Chairman and Chief Executive Omar Ishrak.

    Medtronic's $43 billion Covidien deal may signal future medical-device company mergers.

  • Medtronic is buying Covidien in a $42.9 billion agreement that could increase concerns about the rush of U.S. companies striking deals to cut their tax bills.